SP-624 FOR MAJOR DEPRESSIVE DISORDER
SP-624 is a small molecule with an undisclosed novel mechanism of action that is currently being assessed in a Phase 2 study for its effectiveness in treating patients with major depression. While SP-624 has no effects on multiple receptors (including glutamate receptors), channels and transporters, it does activate presynaptic nerve terminals and postsynaptic neurons. In addition, neuronal connectivity, glutamatergic neuronal function and enhanced Long-term Potentiation in the hippocampus may also contribute to the antidepressant effect. SP-624 will represent a new approach to treating overall depression as well as some subpopulations currently underserved.